Investigation of PNLDC1 gene polymorphism as a risk model of gene signature in predicting platinum response and survival in ovarian cancer
Investigation of PNLDC1 gene polymorphism as a risk model of gene signature in predicting platinum response and survival in ovarian cancer
Sahar Fozouni Sarghein,1,*Farnaz Farzaneh Dehkordi,2
1. Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran 2. Department of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran
Introduction: Introduction: Ovarian cancer is one of the most deadly cancers of women, which is
considered as one of the most important causes of global mortality worldwide. Currently,
one of the most important treatment challenges in this category of patients is the
identification of people at risk without clinical symptoms, which can play an important role
in increasing the survival of these patients. Therefore, the use of biomarkers can be a
potential indicator in identifying platinum treatment response and help in clinical decisions
and improve prognosis
Methods: Materials and methods: In this study, 50 tissue samples from patients with ovarian cancer
after chemotherapy and platinum-based treatment were examined and confirmed by a
pathologist. Also, 50 healthy tissue samples were selected as the control group. Then, DNA
of the samples was extracted using a special kit, and polymorphism of PNLDC1 gene was
analyzed using Tetra-ARMS PCR technique.
Results: Findings: Among the patients, 19 cases (38%) had bilateral involvement and 31 cases (62%)
had unilateral involvement. Also, among 31 patients with unilateral involvement, 17 cases
(55%) had right-sided involvement and 14 cases (45%) had left-sided involvement. Among
the 14 patients with involvement on the left side of the body, 3 (21%) patients had
polymorphisms in the PNLDC1 gene. Among 17 patients with involvement on the right side
of the body, 5 (29%) patients had polymorphism in PNLDC1 gene. Among the 19 patients
with involvement on the left side of the body, 3 (16%) patients had polymorphisms in the
PNLDC1 gene. There was a no significant relationship between polymorphism in PNLDC1
gene and ovarian cancer disease. According to the results and statistical analysis, there was
no relationship between the PNLDC1 gene polymorphism as a risk of the gene signature
model in predicting survival and platinum response.
Conclusion: Conclusion: The present study showed that PNLDC1 gene polymorphism is not associated
with ovarian cancer and cannot be used as a biomarker. However, for a better understanding
of the relationship between these polymorphisms and the risk of ovarian cancer, more studies
with a larger sample size on other races, ethnicities and geographical regions are needed.